Crescent Pharma recalls Ramipril 5mg capsules due to manufacturing error
The recall of Ramipril 5mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market position in the cardiovascular segment. This situation requires close monitoring to assess potential impacts on sales forecasts and regulatory compliance.
Company
Crescent Pharma Limited
Asset
Crescent
Indication
Cardiovascular / ACE Inhibitor
Status
Under Review
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
The recall of Ramipril 5mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market position in the cardiovascular segment. This situation requires close monitoring to assess potential impacts on sales forecasts and regulatory compliance.
Why it matters
The recall of Ramipril 5mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market position in the cardiovascular segment. This situation requires close monitoring to assess potential impacts on sales forecasts and regulatory compliance.
What changed
Safety Signal
Analysis
Crescent Pharma Limited is recalling a batch of Ramipril 5 mg Capsules due to a potential manufacturing error.
The recall of Ramipril 5mg capsules by Crescent Pharma due to a manufacturing error poses significant risks to the company's reputation and market position in the cardiovascular segment. This situation requires close monitoring to assess potential impacts on sales forecasts and regulatory compliance.
Monitor for updates on the recall process and any regulatory actions taken by health authorities.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.